Clinical trials: Evaluation Studies
Lung Cancer, Breast Cancer
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is an open, multicenter, dose-escalation and cohort-expansion non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Lutetium [177Lu]…
- Conditions
- Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Solid Tumors
- Trial name
- NCT07274852
- Testing
- Lutetium [177Lu] BL-ARC001
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Amnestic Mild Cognitive Impairment
CTA-MCI: Cognitive Control Training in Patients With Amnestic Mild Cognitive Impairment(CTA-MCI)
This study evaluates the efficacy and mechanism of internet-based cognitive control training on episodic memory function in patients with amnestic Mild Cognitive Impairment(aMCI).
- Trial name
- CTA-MCI (NCT03133052)
- Testing
- internet-based adaptive cognitive control training program
- Where
- China
- Volunteers
- 70 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hypertension, Renovascular
A Study to Evaluate Renal Fibrosis Using MRI Techniques
The purpose of this study is to evaluate whether or not an MRI technique (quantitative magnetization transfer or qMT) in narrowing human kidneys is feasible, reproducible, and predicts recovery.
- Trial name
- NCT04508049
- Testing
- qMT-MRI to detect fibrosis.
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Migraine, Migraine With Aura
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- ASCEND (NCT04406649)
- Testing
- Dihydroergotamine
- Where
- 44 sites in United States
- Volunteers
- 482 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Osteoporosis
A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients
This is a Multi-Center, Randomized, Double-Blind, Dose Escalation, Placebo Parallel Controlled PhaseⅠClinical study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics, Immunogenicity with Multiple…
- Trial name
- NCT04435158
- Testing
- SHR-1222
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group trial evaluating mepolizumab 100 mg against placebo given every 4 weeks through subcutaneous (SC) injection.
- Trial name
- NCT02105948
- Testing
- Mepolizumab
- Where
- 116 sites in United States, Australia and 14 more
- Volunteers
- 837 people
- Sponsor
- GlaxoSmithKline
Meningococcal Disease
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)
The purpose of this extension study is to evaluate the immunogenicity and safety of a booster dose of a MenABCWY vaccine, administered 24 months after completion of the primary vaccination series, in subjects who previously…
- Trial name
- NCT01992536
- Testing
- MenABCWY+OMV, MenABCWY+¼OMV
- Where
- 13 sites in United States, Poland
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder
Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
This phase I trial tests the safety, side effects, and best dose of allogeneic CD6 chimeric antigen receptor T regulatory cells (CD6-CAR Tregs) in treating patients who have chronic graft versus host disease (cGVHD) after an…
- Conditions
- Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease
- Trial name
- NCT05993611
- Testing
- Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Acute Stroke
A Study to Evaluate the Effects of the Neuroflo Device in People Who Have Had a Stroke
Patients with acute ischemic stroke and persistent arterial occlusion following failed mechanical revascularization, who can undergo NeuroFlo treatment within 18 hours of last time symptom free, will be eligible for enrollment to…
- Trial name
- PAO (NCT00653536)
- Testing
- NeuroFlo
- Where
- United States
- Sponsor
- University of California, Los Angeles
IgA Nephropathy
A Phase IIa Study in Primary IgA Nephropathy Patients
This is a phase IIa, multicenter, single-arm, open-label study to evaluate the safety and efficacy of XH-S003 in patients with primary IgA nephropathy
- Trial name
- NCT07634744
- Testing
- XH-S003 Capsule
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Acute Ischemic Stroke
A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant
This is a phase II, open-label, single-arm, exploratory study to evaluate the intracranial arterial recanalization of multiple doses of LT3001 drug product in participant with acute ischemic stroke (AIS)
- Trial name
- NCT07890298
- Testing
- LT3001 Drug Product
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Overweight , Obesity
Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07778693
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 760 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Critical Illness
Relationship Between Pulse Pressure and Stroke Volume in the Critically Ill Patients: The ANDROMEDA-PEGASUS Study
The goal of this study is to assess the predictive capacity of pulse pressure to estimate stroke volume, as assessed by bedside echocardiography in critically ill patients.
- Trial name
- NCT06737614
- Where
- 3 sites in Brazil, Chile and 1 more
- Volunteers
- 1,500 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Type 2 Diabetes Mellitus
The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes
The purpose of the study is to evaluate the effect of Glucerna SR treating newly-diagnosed type 2 diabetes patients (NDM) on glycemic stability, with the application of CGMS (continuous glucose monitoring system) and to further…
- Trial name
- NCT02248714
- Testing
- Glucerna SR
- Where
- China
- Volunteers
- 131 people
- Sponsor
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital
IBS-D (Diarrhea-predominant)
Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder affecting 15-20% of people in industrialized countries, often presenting as abdominal discomfort, pain, and altered bowel habits, significantly impacting…
- Trial name
- PROREDI (NCT06676514)
- Testing
- Probiotic Clostridium butyricum CBM588®, Standard of care IBS-D treatment
- Where
- Italy
- Volunteers
- 405 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Healthy Volunteers
Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension
This study will evaluate the amount of drug that reaches the circulation when a subject takes the test (liquid) formulation compared to the reference (capsule) formulation.
- Trial name
- NCT02521714
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Celgene
Type II Diabetes Mellitus
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects
This study is an open-label, randomized, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-388 in healthy subjects
- Trial name
- CKD-371 (NCT05544214)
- Testing
- CKD-371
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy
A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as three different formulations in adult healthy participants.
- Trial name
- NCT05136404
- Testing
- Selpercatinib
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Loxo Oncology, Inc.
Plasma Cell Myeloma Refractory
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
This is a first-in-human study of SAR446523 conducted in patients with RRMM. The study consists of two parts: Dose escalation (Part A): In this part, up to several dose levels (DLs) of SAR446523 will be explored to determine the…
- Trial name
- NCT06630806
- Testing
- SAR446523
- Where
- 19 sites in United States, Australia and 5 more
- Volunteers
- 87 people
- Sponsor
- Sanofi
Hematologic Diseases
Evaluation of the Immune Response to Sars-Covid-19 Vaccines in Haematological Patients: Prospective Single Center Study
The main objective of this study is to investigate the humoral immune response to COVID-19 vaccines in haematological patients, by testing SARS-CoV-2 seroconversion
- Trial name
- Hema-C19-Vax (NCT05074706)
- Testing
- IgG antibodies to Sars-Cov-2, QuantiFERON SARS-CoV-2 test
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- University of Milano Bicocca